⌘K

07:00:26·65d

SECFiling

NewAmsterdam Pharma Company N.V. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

NAMS· NewAmsterdam Pharma Company N.V.

Health Care

Original source

Companies

NAMS
NewAmsterdam Pharma Company N.V.
Health Care

Recent analyst ratings

Mar 18UpdateTruist$57.00
Oct 20UpdateH.C. Wainwright$52.00
Aug 25UpdateWells Fargo$45.00
Jul 17UpdateGoldman$27.00
Jun 17UpdateCitigroup$42.00
Jun 10UpdateStifel$44.00

Related

SEC4d
SEC Form PRE 14A filed by NewAmsterdam Pharma Company N.V.
ANALYST36d
Truist initiated coverage on NewAmsterdam Pharma with a new price target
INSIDER42d
Director Lange Louis G sold $1,357,230 worth of Ordinary Shares (44,619 units at $30.42), decreasing direct ownership by 81% to 10,360 units (SEC Form 4)
SEC43d
SEC Form 144 filed by NewAmsterdam Pharma Company N.V.
INSIDER44d
Director Lange Louis G sold $828,950 worth of Ordinary Shares (28,186 units at $29.41) and exercised 44,619 in-the-money units of Ordinary Shares at a strike of $11.50, increasing direct ownership by 431% to 54,979 units (SEC Form 4)
INSIDER45d
Chief Scientific Officer Kastelein Johannes Jacob Pieter converted options into 300,000 units of Ordinary Shares and sold $9,090,868 worth of Ordinary Shares (300,000 units at $30.30) (SEC Form 4)
SEC48d
SEC Form 144 filed by NewAmsterdam Pharma Company N.V.
INSIDER52d
Chief Executive Officer Davidson Michael H. converted options into 443,707 units of Ordinary Shares and sold $14,753,258 worth of Ordinary Shares (443,707 units at $33.25) (SEC Form 4)